The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: A meta-analysis

Chen, Yueqiao; Bai, Wenjie; Mao, Dewen; Long, Fuli; Wang, Na; Wang, Kejing; Shi, Qixin

doi:10.17219/acem/155017

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the sex differences between men and women, we recommend that the PERIOD score may be helpful in women and people with and without type 2 diabetes. 54,55 Interestingly, the PERIOD score had general applicability both in the middle-aged (< 65 yrs) and elderly groups (≥ 65 yrs), without the need for additional threshold settings. 56 In hepatological practice, we identified dual cut-off approach (for sensitivity ≥90% was .098; for specificity ≥90% was .378, respectively) to improve the diagnostic certainty of screening high-risk groups of MAFLD-CKD.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, although the diagnostic performances of the PRO‐C3, PRO‐C6 and PERIOD score were essentially similar in different patient groups, whether male or female, or with or without type 2 diabetes 52,53 ; diabetes is an independent risk factor for CKD, and in combination with other metabolic disorders (such as MAFLD) will potentially further accelerate the development of CKD. Considering the sex differences between men and women, we recommend that the PERIOD score may be helpful in women and people with and without type 2 diabetes 54,55 . Interestingly, the PERIOD score had general applicability both in the middle‐aged (< 65 yrs) and elderly groups (≥ 65 yrs), without the need for additional threshold settings 56 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Tang,

Sun,

Song

et al. 2024

Liver International

View full text Add to dashboard Cite

BackgroundMetabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).MethodsA derivation and independent validation cohort of 750 and 129 Asian patients with biopsy‐confirmed MAFLD were included. Serum PRO‐C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.ResultsThe study included two Asian cohorts (n = 180 with MAFLD–CKD; mean‐eGFR: 94.93 mL/min/1.73 m2; median‐urinary albumin‐to‐creatinine ratio: 6.58 mg/mmol). PRO‐C3 was associated with the severity of MAFLD‐CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non‐invasive score (termed PERIOD) including PRO‐C3 efficiently predicted MAFLD‐CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO‐C3‐based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).ConclusionsThe PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO‐C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Tang,

Sun,

Song

et al. 2024

Liver International

View full text Add to dashboard Cite

show abstract

“…NAFLD increases the incidence of CKD. One study demonstrated that the odds of CKD were significantly higher in patients with NAFLD than in controls (OR = 1.95) [ 24 ]. Le et al analyzed data from 1999–2016 National Health and Nutrition Examination Survey and reported that the prevalence of NAFLD with renal insufficiency increased significantly from 5.7% in 1999–2000 to 7.7% in 2015–2016.…”

Section: Discussionmentioning

confidence: 99%

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

Yu,

Chen,

Cheng

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Background Disease-related stress can trigger the occurrence of herpes zoster (HZ). Fatty liver disease (FLD) can have adverse effects on the human body and may induce stress in affected individuals. In this study, we investigated whether FLD is associated with an elevated risk of HZ. Methods For this study, we utilized data from the National Health Insurance Research Database, patients with FLD from 2000 to 2017 were observed (follow-up until 2018). Patients were considered to have FLD if they had at least two outpatient visits or at least one admission record with a diagnostic code of FLD. Patients with FLD were matched 1:1 by age, sex, comorbidities, and index year with control patients. Additionally, the FLD was further categorized into non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD) groups. Multivariable Cox proportional hazards model was used to calculate the incidence rate and adjusted hazard ratio (aHR) of HZ for FLD and AFLD and for various age groups, sex and comorbidities. Cumulative incidence curve for HZ was plotted through the Kaplan–Meier method, and p-value was calculated using the log-rank test. Results After 1:1 propensity-score matching, each cohort comprised 62,418 patients. The FLD cohort was further divided into NAFLD and AFLD groups, which respectively comprised 55,709 and 6709 patients. The FLD cohort had a risk of HZ significantly higher than that of the control cohort (aHR = 1.06; p < 0.001). Additionally, the NAFLD group exhibited a significantly higher risk of HZ than did the AFLD group (aHR = 1.22; p < 0.001). Among patients without any comorbidities, those with FLD had a higher risk of HZ than did those without FLD (aHR = 1.14; p < 0.001). Conclusion Patients with FLD are at an increased risk of HZ development. Additionally, NAFLD is associated with a higher risk of HZ than AFLD. Therefore, patients with NAFLD should be informed of their increased risk of HZ.

show abstract

“…These conditions are highly prevalent, so it is not surprising that many occur in the same patients (Table 1) [17][18][19][20][21][22][23]. NAFLD is associated with a high prevalence of obesity (51%), T2DM (23%) and metabolic syndrome (43%), as well as dyslipidaemia (69%) and hypertension (39%) [24].…”

Section: Overlapping Diseasesmentioning

confidence: 99%

“…The risk of CKD in patients with NAFLD is also increased (HR 1.43-1.95) [17,21], and the presence of T2DM doubles the risk of CKD in patients with NAFLD (OR, 1.8) [21]. CKD in patients with NAFLD is associated with a greater risk of mortality compared to CKD in patients without NAFLD (HR, 2.3-4.8) [27].…”

Section: Overlapping Diseasesmentioning

confidence: 99%

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Zannad,

Sanyal,

Butler

et al. 2024

J Intern Med

View full text Add to dashboard Cite

Steatotic liver disease (SLD) is a worldwide public health problem, causing considerable morbidity and mortality. Patients with SLD are at increased risk for major adverse cardiovascular (CV) events, type 2 diabetes mellitus and chronic kidney disease. Conversely, patients with cardiometabolic conditions have a high prevalence of SLD. In addition to epidemiological evidence linking many of these conditions, there is evidence of shared pathophysiological processes. In December 2022, a unique multi‐stakeholder, multi‐specialty meeting, called MOSAIC (Metabolic multi Organ Science Accelerating Innovation in Clinical Trials) was convened to foster collaboration across metabolic, hepatology, nephrology and CV disorders. One of the goals of the meeting was to consider approaches to drug development that would speed regulatory approval of treatments for multiple disorders by combining liver and cardiorenal endpoints within a single study. Non‐invasive tests, including biomarkers and imaging, are needed in hepatic and cardiorenal trials. They can be used as trial endpoints, to enrich trial populations, to diagnose and risk stratify patients and to assess treatment efficacy and safety. Although they are used in proof of concept and phase 2 trials, they are often not acceptable for regulatory approval of therapies. The challenge is defining the optimal combination of biomarkers, imaging and morbidity/mortality outcomes and ensuring that they are included in future trials while minimizing the burden on patients, trialists and trial sponsors. This paper provides an overview of some of the wide array of CV, liver and kidney measurements that were discussed at the MOSAIC meeting.

show abstract

The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: A meta-analysis

Abstract: et al. The relationship between non-alcoholic fatty liver disease and incidence of chronic kidney disease for diabetic and non-diabetic subjects: A meta-analysis [published online as ahead of print on November 22, 2022].

Cited by 6 publications

References 30 publications

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort

Non-alcoholic fatty liver disease associated with greater herpes zoster risk than alcoholic fatty liver disease

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Contact Info

Product

Resources

About